[25] Anebulo Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Anebulo Pharmaceuticals, Inc. has filed a Form 25 to remove its common stock from listing and registration on The Nasdaq Stock Market LLC. This step means the company’s common shares will cease to be traded on Nasdaq once the delisting process is completed under the Securities Exchange Act of 1934.

The company states that it has reasonable grounds to believe it meets all requirements to file this notice, and the document is signed by its Chief Executive Officer and Interim Chief Financial Officer. Investors will likely need to trade the shares on alternative markets after the Nasdaq listing is withdrawn.

Insights

Equity market structure analyst

Anebulo is formally delisting its common stock from Nasdaq.

Anebulo Pharmaceuticals has initiated the legal process to remove its common stock from listing and registration on Nasdaq by filing Form 25 under the Securities Exchange Act. This is a structural change in where and how the shares can trade, not an operating result.

The notice indicates the company believes it meets all requirements for this filing and is signed by senior management. Once the delisting becomes effective, trading will likely shift to over-the-counter or other venues, and liquidity and visibility can differ from a national exchange.

Subsequent company communications and future regulatory filings may clarify the company’s post-delisting trading venue and any impact on shareholder rights or reporting practices under the Exchange Act.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-40388

ANEBULO PHARMACEUTICALS, INC.

Exchange: The Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Anebulo Pharmaceuticals, Inc.

1017 Ranch Road 620 South, Suite 107

Lakeway, TX 78734

(512) 598-0931

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Stock, $0.001 par value per share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

	☐	17 CFR 240.12d2-2(a)(1)
	☐	17 CFR 240.12d2-2(a)(2)
	☐	17 CFR 240.12d2-2(a)(3)
	☐	17 CFR 240.12d2-2(a)(4)
	☐	Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
	☒	Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Anebulo Pharmaceuticals, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25, and has caused this notice to be signed on its behalf by the undersigned duly authorized person.

	Anebulo Pharmaceuticals, Inc.
Date: February 17, 2026	By:	/s/ Richard Anthony Cunningham
	Name:	Richard Anthony Cunningham
	Title:	Chief Executive Officer and Interim Chief Financial Officer

FAQ

What did Anebulo Pharmaceuticals (ANEB) file with respect to its Nasdaq listing?

Anebulo Pharmaceuticals filed a Form 25 to remove its common stock from listing and registration on The Nasdaq Stock Market. This formally starts the delisting process under the Securities Exchange Act of 1934 and will move trading away from the Nasdaq exchange.

Which securities of Anebulo Pharmaceuticals (ANEB) are affected by this Form 25?

The filing covers Anebulo Pharmaceuticals’ common stock with a par value of $0.001 per share. This class of securities is being removed from listing and registration on The Nasdaq Stock Market, changing where and how these shares can be traded going forward.

Is Anebulo Pharmaceuticals’ delisting from Nasdaq described as voluntary or exchange-driven?

The Form 25 indicates the issuer has complied with exchange rules and the requirements of 17 CFR 240.12d2-2(c), which governs voluntary withdrawal. This language signals that Anebulo Pharmaceuticals is taking affirmative steps to remove its common stock from Nasdaq listing and registration.

Who signed Anebulo Pharmaceuticals’ Form 25 delisting notice?

The notice was signed on behalf of Anebulo Pharmaceuticals by Richard Anthony Cunningham, who is identified as Chief Executive Officer and Interim Chief Financial Officer. His signature certifies the company believes it meets all requirements necessary to file the Form 25 under the Exchange Act.

What does Anebulo’s Nasdaq delisting mean for ANEB shareholders?

The delisting means Anebulo’s common stock will no longer trade on Nasdaq once the Form 25 becomes effective. Shareholders may need to trade on alternative markets, such as over-the-counter venues, where liquidity, pricing transparency, and research coverage can differ from a national exchange.